皮下注射贝林妥欧单抗治疗复发或难治性B细胞急性淋巴细胞白血病成人患者:一项多中心、单臂、1/2期试验的事后安全性与活性分析
该多中心单臂1/2期试验事后分析纳入88例复发或难治性B细胞急性淋巴细胞白血病成人患者,评估皮下贝林妥欧单抗两个剂量方案(250μg/500μg组36例,500μg/1000μg组52例)的安全性与活性。两组完全缓解或伴部分血液学恢复的完全缓解率分别为75%和79%,常见3-4级不良事件为中性粒细胞减少、细胞因子释放综合征和免疫效应细胞相关神经毒性综合征,无治疗相关死亡。基于疗效、安全性和药代动力学数据,250μg/500μg方案被选为推荐2期剂量。
要点
- 皮下贝林妥欧单抗250μg/500μg组36例中27例(75%)达完全缓解或伴部分血液学恢复的完全缓解。
- 500μg/1000μg组52例中41例(79%)达完全缓解或伴部分血液学恢复的完全缓解。
- 基于疗效、安全性和药代动力学数据,250μg/500μg方案被选为推荐2期剂量。
核心结论
- 皮下贝林妥欧单抗250μg/500μg和500μg/1000μg两个剂量方案在复发或难治性B细胞急性淋巴细胞白血病成人患者中显示出有前景的初步活性和可控的安全性。
- 基于包括疗效、安全性和药代动力学数据的总体数据,皮下贝林妥欧单抗250μg/500μg剂量方案被选为推荐2期剂量。
- 试验的2期部分正在进行中,以进一步评估皮下贝林妥欧单抗的活性和缓解持续时间。
研究设计与样本
- 本研究的来源为一项多中心、单臂、1/2期试验的事后分析,纳入剂量递增期、剂量扩展期及药代动力学评估队列的患者。
- 患者来自11个国家的44家医院,入组时间为2021年10月18日至2024年9月23日。
- 纳入标准为年龄18岁及以上、复发或难治性B细胞急性淋巴细胞白血病、骨髓原始细胞至少5%、东部肿瘤协作组体能状态评分2分或以下。
- 共88例患者纳入分析(数据截止2024年11月28日),其中36例(41%)接受250μg/500μg方案,52例(59%)接受500μg/1000μg方案。
- 250μg/500μg组为第1周期第1周每日一次皮下注射250μg,此后每周三次500μg;500μg/1000μg组按相同 schedule 给予500μg后1000μg;每个治疗周期含4周治疗期和1周无治疗间期,患者接受2至5个周期。
主要发现
- 250μg/500μg组36例中27例(75%)达完全缓解或伴部分血液学恢复的完全缓解,500μg/1000μg组52例中41例(79%)达完全缓解或伴部分血液学恢复的完全缓解。
- 最常见的3-4级不良事件为中性粒细胞减少(19例[22%])、细胞因子释放综合征(CRS;18例[20%])和免疫效应细胞相关神经毒性综合征(ICANS;15例[17%])。
- 严重不良事件发生于88例中的70例(80%),包括CRS(33例[38%])、ICANS(20例[23%])和神经毒性(6例[7%])。
- 未报告治疗相关死亡。
- 皮下给药后观察到与剂量成比例暴露的一致药代动力学。
关键数值与推荐
- 剂量扩展期的主要终点为前两个周期内的完全缓解或伴部分血液学恢复的完全缓解,本研究以此为主要结局。
- 缓解率采用双侧精确80%置信区间(Clopper-Pearson法)计算。
- 入组人群包括55例(63%)男性和33例(38%)女性;56例(64%)为白人,6例(7%)为亚洲人,3例(3%)为黑人或非裔美国人,2例(2%)为美洲印第安人或阿拉斯加原住民,20例(23%)为其他。
- 33例(38%)患者报告西班牙裔或拉丁裔族裔。
- 中位随访时间为5个月(IQR 3-9)。
临床怎么用
- 作者指出,皮下贝林妥欧单抗250μg/500μg和500μg/1000μg两个剂量方案在复发或难治性B细胞急性淋巴细胞白血病成人患者中显示出有前景的初步活性和可控的安全性。
- 基于总体数据,皮下贝林妥欧单抗250μg/500μg剂量方案被选为推荐2期剂量。
- 试验的2期部分正在进行中,以进一步评估皮下贝林妥欧单抗的活性和缓解持续时间。
局限性
- 本研究为事后分析。
- 本文报告的中位随访时间为5个月(IQR 3-9)。
- 原文指出试验的2期部分正在进行中,以进一步评估皮下贝林妥欧单抗的活性和缓解持续时间。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Two doses of subcutaneous blinatumomab in patients with relapsed or refractory B-cell acute lymphoblastic leukaemia were identified as preliminary recommended phase 2 doses, based on the dose-escalation phase of this multicentre single-arm, phase 1/2 trial. Here, we aim to further study the safety, activity, and pharmacokinetics of these doses in all participants who have received them, including those treated in the completed phase 1b expansion part of the study. METHODS: We did a post-hoc analysis of data from patients enrolled in the dose-escalation and dose-expansion phases and in the pharmacokinetic evaluation cohort of this multicentre, single-arm, phase 1/2 study. Patients were recruited from 44 hospitals in 11 countries. Eligible participants were aged 18 years or older with relapsed or refractory B-cell acute lymphoblastic leukaemia, at least 5% of blasts in the bone marrow, and an Eastern Cooperative Oncology Group performance status of 2 or lower. Patients received either 250 μg subcutaneous blinatumomab once daily in week 1 of cycle 1 and then 500 μg three times weekly thereafter (250 μg/500 μg group), or 500 μg and then 1000 μg subcutaneous blinatumomab on the same schedule (500 μg/1000 μg group), previously identified as the preliminary recommended phase 2 doses. Each treatment cycle included a 4-week treatment period and a 1-week treatment-free interval. Patients received between two and five cycles. The primary endpoint for the dose-expansion phase was complete remission or complete remission with partial haematological recovery within the first two cycles, which was used as the primary outcome for this study. Data were pooled from all cohorts of the same dose level to form two dose groups. The response rates, adverse event incidence, and pharmacokinetics were summarised in each dose group separately and compared descriptively. Response was calculated with two-sided exact 80% CIs (Clopper-Pearson method). This study is registered with ClinicalTrials.gov, NCT04521231; phase 1 is complete, and phase 2 is active but not recruiting. FINDINGS: Participants were recruited from Oct 18, 2021, to Sept 23, 2024, and median follow-up for the analyses was 5 months (IQR 3-9). Of the 88 patients included in the analysis at the data cutoff of Nov 28, 2024, 36 (41%) were treated with the 250 μg/500 μg regimen and 52 (59%) with the 500 μg/1000 μg regimen. The enrolled population comprised 55 (63%) male and 33 (38%) female participants; 56 (64%) were White, six (7%) Asian, three (3%) Black or African American, two (2%) American Indian or Alaska Native, and 20 (23%) other. Hispanic or Latino ethnicity was reported for 33 (38%) patients. 27 (75%) of 36 patients in the 250 μg/500 μg group and 41 (79%) of 52 in the 500 μg/1000 μg group showed complete remission or complete remission with partial haematological recovery. The most common grade 3-4 adverse events were neutropenia (19 [22%] patients), cytokine release syndrome (CRS; 18 [20%] patients), and immune effector cell-associated neurotoxicity syndrome (ICANS; 15 [17%] patients). Serious adverse events occurred in 70 (80%) of 88 patients and included CRS (33 [38%] patients), ICANS (20 [23%] patients), and neurotoxicity (six [7%] patients). No treatment-related deaths were reported. Consistent pharmacokinetics with dose-proportional exposures was observed following subcutaneous administration. Based on the totality of data, including efficacy, safety, and pharmacokinetic data, the subcutaneous blinatumomab dose regimen of 250 μg/500 μg was selected as the recommended phase 2 dose. INTERPRETATION: Treatment with subcutaneous blinatumomab at the two dose regimens of 250 μg/500 μg and 500 μg/1000 μg resulted in promising preliminary activity and a manageable safety profile in adults with relapsed or refractory B-cell acute lymphoblastic leukaemia. The phase 2 part of the trial is ongoing to further evaluate subcutaneous blinatumomab activity and duration of response. FUNDING: Amgen.
引用
- Jabbour E, Lussana F, Martínez-Sánchez P, et al. Subcutaneous blinatumomab in adults with relapsed or refractory B-cell acute lymphoblastic leukaemia: post-hoc safety and activity analysis from a multicentre, single-arm, phase 1/2 trial. Lancet Haematol. 2025. PMID: 40532723. doi:10.1016/S2352-3026(25)00144-9
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。